| Date | Title | | | 09/20/17 | Natera Selected for Circulating Tumor DNA Study in Bladder Cancer| Denmark's Aarhus University to Use Signatera™ ctDNA Technology in Longitudinal Study
SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™ (RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer. Signatera™ was re... |
| | | 08/21/17 | Natera Launches Signatera™ Personalized Circulating Tumor DNA Technology for Cancer Research| SAN CARLOS, Calif., Aug. 21, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual's tumor, for research use only (RUO) by oncology researchers and biopharmaceutical companies.
Already in clinical validation with multiple world-leading cancer institutes, SignateraTM offers a no... |
| | | 08/08/17 | Natera Reports Second Quarter 2017 Financial Results| SAN CARLOS, Calif., Aug. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2017 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $53.6 million in the second quarter of 2017 compared to $52.0 million in the second quarter of ... |
| | | 08/01/17 | Natera Inc. Announces Second Quarter 2017 Earnings Conference Call| SAN CARLOS, Calif., Aug. 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its second quarter ended June 30, 2017 after the market close on August 8, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Conference Call Information:
Event: ... |
| | | 07/31/17 | Large Study Shows Natera’s Panorama Prenatal Screen To Be Highly Accurate in Identifying DNA Microdeletions Associated with Serious Health Implications| Study evaluated screening performance for 22q11.2, 1p36, Prader-Willi,
Angelman, and cri-du-chat microdeletion syndromes
Using new testing methodology, positive predictive values improved to
44.2% for 22q11.2 deletion syndrome and 31.7% for four other
microdeletion disorders
False positive rates decreased to 0.07% for 22q11.2 and 0.07% for the
other four disorders combined
Prevalence in... |
| | | 05/09/17 | Natera Reports First Quarter 2017 Financial Results| SAN CARLOS, Calif., May 9, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Processed greater than 121,000 tests, including greater than 114,000 tests accessioned in Natera's laboratory and greater than 6,300 units processed through i... |
| | | 05/08/17 | Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT| A NIPT to screen for single gene disorders using cfDNA
SAN CARLOS, Calif., May 8, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in genetic testing, announced the launch of Vistara, a non-invasive prenatal test (NIPT) to screen single-gene disorders. Vistara is a complement to Natera's market-leading Panorama® non-invasive prenatal test (NIPT) and screens for new mutations in 30 genes that have a combined incidence rate of nearly 1 in 600, which is higher than that of Down syndrome.1,... |
| | | 05/04/17 | Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors| Experienced Healthcare Executive Adds Deep Experience in Managed Care and Market Access
SAN CARLOS, Calif., May 4, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Gail Marcus as member of the board of directors, effective March 2017.
Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International since 2015.... |
| | | 05/02/17 | Natera Inc. Announces First Quarter 2017 Earnings Conference Call| SAN CARLOS, Calif., May 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its first quarter ended March 31, 2017 after the market close on May 9, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Conference Call Information:
Event:
N... |
| | | 04/26/17 | Study in Nature Shows Early Relapse Detection in Lung Cancer Using Natera's Technology for ctDNA Analysis| Relapse detected up to 347 days earlier than standard of care, with sensitivity and specificity exceeding 90%
SAN CARLOS, Calif. and LONDON, April 26, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, and Cancer Research UK, University College of London (UCL) Cancer Institute and the Francis Crick Institute today announced the publication of results from the first 100 patients in the Cancer Research UK-funded TRACERx study (Tracking Cancer Evolutio... |
| | | 03/07/17 | Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results| SAN CARLOS, Calif., March 7, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2016 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $49.3 million in the fourth quarter of 2016 compared to $52.9 million... |
| | | 03/01/17 | Natera, Inc. Announces Launch of Evercord™ Cord Blood and Tissue Banking Service| Launch Expands Natera's Leadership Position in Women's Reproductive Health
SAN CARLOS, Calif., March 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in genetic testing, today announced the upcoming launch of Evercord; a new offering being made commercially available in the second quarter of 2017 that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. ... |
| | | 02/28/17 | Natera Inc. Announces Fourth Quarter and Fiscal Year 2016 Earnings Conference Call| SAN CARLOS, Calif., Feb. 28, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2016 after the market close on March 7, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.
Confe... |
| | | 02/03/17 | Natera Inc. Announces Appointment of Mike Brophy as New Chief Financial Officer| Former Chief Financial Officer Herm Rosenman to Join Natera's Board of Directors
SAN CARLOS, Calif., Feb. 3, 2017 /PRNewswire/ -- Natera Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Mike Brophy as Natera's new chief financial officer, effective February 1, 2017. Mr. Brophy replaces Herman ("Herm") Rosenman, who joined the Company's board of directors effective February 1, 2017 following his three-year tenure as Natera's current CFO, a pos... |
| | | 01/17/17 | Natera Announces Results From DNAFirst Study, Validating Use Of NIPT In Routine Prenatal Care| Results demonstrate clinical utility of NIPT as first line screen in a general population
Study results published in Genetics in Medicine
SAN CARLOS, Calif., Jan. 17, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the results from the DNAFirst trial, showing that non-invasive prenatal screening tests (NIPT) can be effectively and appropriately offered as a primary screen for all pregnant women, regardless of risk due to matern... |
| | | 01/10/17 | Natera Inc. Terminates NIPT Distribution Agreement with Bioreference Labs| SAN CARLOS, Calif., Jan. 10, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Natera intends to promote Panorama directly to clinicians, who previously ordered this test through Bio-Reference. Natera also plans to promote its Horizon carrier screen test to these clinicians, which it had not done previously.
... |
| |
|
